This randomized, positive control, multicentre trial is designed to compare the analgesic efficacy and safety of nalbuphine hydrochloride injection and morphine hydrochloride injection for perioperative tumor ablation.

Sedation and analgesia use in tumor ablation is a necessary part of the procedure. However, the optimal medicine for sedation and analgesia for tumor ablation remains controversial. Currently, morphine is a traditional opioid used for pain control and anaesthesia. As no publications have compared the anaesthetic and analgesic effects between nalbuphine and morphine during tumor ablation, this trial aims to compare the analgesic efficacy and safety of nalbuphine and morphine for perioperative tumor ablation. In addition, other endpoints in term of perioperative analgesia indexes, such as ablation time, daily dose, analgesia satisfaction, quality of life, and safety, etc. will be compared.

Inclusion Criteria:

• Patients requiring tumor ablation;
• Voluntarily participate and sign the informed consent.

Exclusion Criteria:

• Allergic to contrast agent, test drug or other ingredients;
• With a history of substance abuse, chronic pain and mental illness;
• Use of any monamine oxidase inhibitor within 14 days prior to randomization;
• Pregnant or breastfeeding;
• Cannot tolerate ablation due to other reasons;
• Cannot express their wishes correctly;
• Poor compliance, unable to complete the trial;
• Have participated in other drug trials within 30 days prior to enrollment;
• Judged by the researcher to be unsuitable.

Other researchers can contact the PI for data.